The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial.
Claus Rodel
Honoraria - Roche; Sanofi
Research Funding - Merck KGaA; Roche; Sanofi
Torsten Liersch
No relevant relationships to disclose
Rainer Fietkau
Honoraria - Sanofi
Werner Hohenberger
No relevant relationships to disclose
Ullrich Graeven
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Torsten Hothorn
No relevant relationships to disclose
Dirk Arnold
Consultant or Advisory Role - Amgen; Merck Serono; Roche; Sanofi
Honoraria - Amgen; Merck Serono; Roche; Sanofi
Research Funding - Merck Serono; Roche; Sanofi
Hans-Rudolf Raab
No relevant relationships to disclose
Christian Wittekind
No relevant relationships to disclose
Clemens F Hess
No relevant relationships to disclose
Ludger Staib
No relevant relationships to disclose
Heinz Becker
No relevant relationships to disclose
Rolf Sauer
No relevant relationships to disclose